| 摘要 |
Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reactio n in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter bein g a reactive protein modifying agent. 3DG can be detoxified by reduction to 3- deoxyfructose (3DF), or it can react with endogenous proteins to form advanc ed glycation end-product modified proteins (AGE-proteins), which are believed t o be a contributing cause of diabetic complications. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE- proteins and thereby lessen, reduce and delay diabetic complications, as wel l as methods for assessing a diabetic's risk of developing complications and f or determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product.
|
